Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients

被引:14
|
作者
Pease, Daniel F. [1 ]
Ross, Julie A. [2 ]
Poynter, Jenny N. [2 ]
Nguyen, Phuong L. [3 ]
Hirsch, Betsy [4 ]
Cioc, Adina [5 ]
Roesler, Michelle A. [2 ,6 ]
Warlick, Erica D. [7 ]
机构
[1] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA
[2] Univ Minnesota, Dept Pediat, Minneapolis, MN 55454 USA
[3] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA
[4] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[5] VA Med Ctr, Hematopathol, Minneapolis, MN 55417 USA
[6] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
关键词
Myelodysplastic syndromes; Hematologic malignancies; Drug therapy; Bone marrow transplantation; STEM-CELL TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; RETROSPECTIVE MULTICENTER ANALYSIS; CONVENTIONAL CARE REGIMENS; IDENTICAL SIBLING DONORS; ACUTE MYELOID-LEUKEMIA; DECISION-ANALYSIS; OLDER PATIENTS; PHASE-III; THERAPY;
D O I
10.1016/j.canep.2015.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The heterogeneous nature of myelodysplastic syndromes (MDS) complicates therapeutic decision making, particularly for newly diagnosed disease. Factors impacting the treatment plan in this early period of disease course are poorly defined. This study determines whether therapeutic choices for newly diagnosed MDS are associated with location of treatment (community or academic), prognostic risk category, and patient age. Methods: The adults in Minnesota with myelodysplastic syndromes (AIMMS) database was utilized in this statewide, prospective population-based study conducted by the University of Minnesota (UMN), Mayo Clinic, and Minnesota Department of Health. Adult (age 20+ years) cases of MDS newly diagnosed starting in April 2010 were invited to participate. This analysis includes patients enrolled during the first study year with 1-year follow-up data. Treatment choices (supportive, active, and transplant) were stratified by the international prognostic scoring system (IPSS) and the revised-IPSS (IPSS-R), then separated into groups by location of care and age (<65 or 65+ years). Academic-based care was any contact with the UMN and Mayo Clinic; community-based care was all other clinical sites. Results: Stratification by IPSS and IPSS-R showed supportive care decreased and active care increased with advancing risk categories (p < 0.0001). Comparing treatment setting, community-based care had 77% supportive and 23% active treatment; academic-based care was 36% supportive, 41% active, and 23% transplant (p < 0.0001). By age groups, patients < 65 years with intermediate, high, or very high risk disease by IPSS-R received 97% active care/transplant, compared to only 52% of patients age 65+. Conclusions: Younger patients and those treated at academic centers had a more aggressive treatment approach. Whether these treatment differences convey improved disease control and mortality, and therefore should be extended more frequently to older and community-based patients, is the subject of ongoing prospective study. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [21] INTENSIVE CHEMOTHERAPY FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    BERNSTEIN, SH
    BRUNETTO, VL
    DAVEY, FR
    MAYER, RJ
    WURSTERHILL, D
    SCHIFFER, CA
    BLOOMFIELD, CD
    BLOOD, 1993, 82 (10) : A196 - A196
  • [22] Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
    Tomlinson, Benjamin
    de Lima, Marcos
    Cogle, Christopher R.
    Thompson, Michael A.
    Grinblatt, David L.
    Pollyea, Daniel A.
    Komrokji, Rami S.
    Roboz, Gail J.
    Savona, Michael R.
    Sekeres, Mikkael A.
    Abedi, Mehrdad
    Garcia-Manero, Guillermo
    Kurtin, Sandra E.
    Maciejewski, Jaroslaw P.
    Patel, Jay L.
    Revicki, Dennis A.
    George, Tracy I.
    Flick, E. Dawn
    Kiselev, Pavel
    Louis, Chrystal U.
    Degutis, Irene S.
    Nifenecker, Melissa
    Erba, Harry P.
    Steensma, David P.
    Scott, Bart L.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (07): : 460e1 - 460e9
  • [23] Myelodysplastic syndromes (MDS): An international practice and treatment survey.
    List, AF
    BLOOD, 2005, 106 (11) : 712A - 712A
  • [24] Patterns of total cost for patients (pts) with active treatment (Tx) of myelodysplastic syndromes (MDS).
    Smith, B. Douglas
    Dezern, Amy Elizabeth
    Binder, Gary
    Rizvi, Syed
    Corvino, Frank A.
    Arikian, Steven R.
    Surinach, Andy
    Lee, Jianyi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Molecular and Diagnostic Testing Patterns in Elderly Patients with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry
    George, Tracy I.
    Cogle, Christopher R.
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Komrokji, Rami S.
    Kurtin, Sandra E.
    Maciejewski, Jaroslaw P.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Flick, E. Dawn
    Kiselev, Pavel
    Louis, Chrystal U.
    Nifenecker, Melissa
    Swern, Arlene S.
    Foucar, Kathryn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S315
  • [26] Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry
    de Swart, Louise
    Smith, Alex
    Fenaux, Pierre
    Symeonidis, Argyris
    Hellstrom-Lindberg, Eva
    Sanz, Guillermo
    Cermak, Jaroslav
    Georgescu, Otilia
    Germing, Ulrich
    MacKenzie, Marius
    Beyne-Rauzy, Odile
    Malcovati, Luca
    Stauder, Reinhard
    Droste, Jackie
    Bowen, David
    de Witte, Theo
    BLOOD, 2010, 116 (21) : 1201 - 1202
  • [27] CYTOGENETIC STUDIES IN 69 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    WEH, HJ
    CALAVREZOS, A
    SEEGER, D
    KUSE, R
    HOSSFELD, DK
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1987, 38 (02) : 166 - 172
  • [28] Serum cytokine levels in patients with myelodysplastic syndromes (MDS).
    Allampallam, K
    Shetty, V
    Mundle, S
    Dutt, D
    Reddy, PL
    Alvi, S
    Galili, N
    Saberwal, GS
    Anthwal, S
    Shaikh, MW
    York, A
    Gezer, S
    Venugopal, P
    Raza, A
    BLOOD, 2001, 98 (11) : 269B - 270B
  • [29] Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices
    Egloff, Shanna Arnold
    Cao, Xiting
    Lachs, Rebecca
    Martin, Casey
    Mattlin, Meredith
    Fennell, Emma
    Rayburn, Dillan
    Schlauch, Daniel
    Kurbegov, Dax
    Ide, Susan
    Battiwalla, Minoo
    LEUKEMIA & LYMPHOMA, 2023, 64 (13) : 2101 - 2112
  • [30] Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
    Sekeres, Mikkael A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (01): : 57 - 63